Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316186 · ClinicalTrials.gov registry record · Phase 2
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
A Phase 2 study of Lung Cancer, Small Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 13
- Study locations
NCT00316186: Completed Phase 2 study of Lung Cancer, Small Cell, sponsored by GlaxoSmithKline.
NCT00316186 is a Phase 2 study of Lung Cancer, Small Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00316186, a Phase 2 study of Lung Cancer, Small Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Primary Outcome
The categories of tumor response were: complete response (complete disappearance of all known lesions determined by 2 measurements not less than 4 weeks apart), partial response (\>50% decrease in measurable lesions for at least 4 weeks with no appearance of new lesions), stable disease (no change in tumor size for at least 8 weeks), progressive disease (\>25% increase in measurements of lesions or appearance of new lesions), and not evaluable. The overall response rate was determined using a sc
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG topotecan
Study Locations (13)
California
- GSK Investigational Site - Concord
- GSK Investigational Site - Sacramento
Florida
- GSK Investigational Site - Boca Raton
- GSK Investigational Site - Hollywood
Arizona
- GSK Investigational Site - Tucson
Illinois
- GSK Investigational Site - Chicago
Indiana
- GSK Investigational Site - Munster
Louisiana
- GSK Investigational Site - Metairie
Missouri
- GSK Investigational Site - St Louis
New York
- GSK Investigational Site - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00316186 record still lists
NCT00316186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Lung Cancer, Small Cell appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.
NCT00316186 lists 13 locations in 11 states (California, Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT00316186 about?
NCT00316186 is a clinical study titled "First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin". This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
What is the current status of trial NCT00316186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2005-06. Estimated completion is 2009-05.
What conditions does trial NCT00316186 study?
This clinical trial studies the following conditions: Lung Cancer, Small Cell.
What interventions are being tested in trial NCT00316186?
The interventions under investigation include: carboplatin (DRUG), topotecan (DRUG).
Who is sponsoring clinical trial NCT00316186?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00316186 being conducted?
This trial has 13 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00316186's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia